DCT

2:21-cv-03070

Celanese Intl Corp v. Anhui Jinhe Industrial Co Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 2:21-cv-03070, C.D. Cal., 04/08/2021
  • Venue Allegations: Venue is alleged in the Central District of California because a substantial part of the events giving rise to the claims occurred in the district, and multiple defendants are incorporated in, reside in, or have regular and established places of business in the district, where they allegedly sell, distribute, or import infringing products.
  • Core Dispute: Plaintiff alleges that Defendant Jinhe's high-intensity sweetener, acesulfame potassium (Ace-K), is manufactured and purified using processes that infringe five of Plaintiff's U.S. patents.
  • Technical Context: The lawsuit concerns the chemical manufacturing processes for acesulfame potassium, a widely used artificial sweetener, focusing on methods to increase purity by minimizing specific chemical byproducts.
  • Key Procedural History: The complaint identifies two distinct patent families, the '546 Patent Family and the '999 Patent Family, which are directed to different stages and aspects of the Ace-K production and purification process. No prior litigation or administrative proceedings are mentioned in the complaint.

A. Case Timeline

Date Event
2014-01-01 Defendant Jinhe USA established.
2016-01-01 Defendant Jinhe allegedly enlarged its Ace-K production capacity.
2016-09-21 Earliest Priority Date for all Asserted Patents ('546, '004, '098, '163, '095).
2018-07-17 U.S. Patent No. 10,023,546 Issued.
2019-02-19 U.S. Patent No. 10,208,004 Issued.
2019-03-19 U.S. Patent No. 10,233,163 Issued.
2020-03-17 U.S. Patent No. 10,590,098 Issued.
2020-03-17 U.S. Patent No. 10,590,095 Issued.
2021-04-08 Complaint Filing Date.

II. Technology and Patent(s)-in-Suit Analysis

A. U.S. Patent No. 10,023,546 - "Acesulfame Potassium Compositions and Processes for Producing Same"

1. The Invention Explained

  • Problem Addressed: Conventional methods for producing acesulfame potassium (Ace-K) generate undesirable impurities, such as 5-chloro-acesulfame potassium, which are difficult and costly to separate from the final product Compl. ¶¶30-32 '546 Patent, col. 1:47-55
  • The Patented Solution: The patent discloses a process that reduces the formation of 5-chloro-acesulfame potassium by controlling the "contact time" of the reaction. The invention specifies that the time between preparing a "cyclizing agent composition" and reacting it with an acetoacetamide salt must be less than 60 minutes, which is claimed to minimize the side reactions that produce the unwanted impurity '546 Patent, abstract '546 Patent, col. 10:60-65
  • Technical Importance: This process claims to produce a higher-purity Ace-K, potentially reducing the need for extensive downstream purification steps and thereby lowering manufacturing costs Compl. ¶35

2. Key Claims at a Glance

  • The complaint asserts independent claim 1 Compl. ¶80
  • Essential elements of claim 1 include:
    • A process for producing a finished acesulfame potassium composition.
    • (a) contacting a cyclizing agent and a solvent to form a cyclizing agent composition.
    • (b) reacting an acetoacetamide salt with the cyclizing agent composition to form a cyclic sulfur trioxide adduct.
    • (c) forming from the adduct a finished acesulfame potassium composition comprising less than 35 wppm 5-chloro-acesulfame potassium.
    • A "wherein" clause requiring the contact time from the beginning of step (a) to the beginning of step (b) to be less than 60 minutes.
  • The complaint does not explicitly reserve the right to assert dependent claims for this patent.

B. U.S. Patent No. 10,208,004 - "Acesulfame Potassium Compositions and Processes for Producing Same"

1. The Invention Explained

  • Problem Addressed: Similar to the '546 Patent, this invention addresses the formation of impurities, specifically 5-chloro-acesulfame potassium, during the synthesis of Ace-K (Compl. ¶32; Compl. ¶33, Compl. ¶¶col. 4:1-4).
  • The Patented Solution: The '004 Patent's solution adds a temperature control element to the time-controlled process. It requires cooling the cyclizing agent composition to a temperature lower than the initial temperature of its constituent parts before reacting it with the acetoacetamide salt '004 Patent, abstract This combination of cooling and a short contact time (less than 60 minutes) is claimed to further reduce or eliminate the formation of the 5-chloro impurity '004 Patent, col. 7:51-57
  • Technical Importance: By adding a specific cooling step, the process provides another parameter to control reaction kinetics, aiming for an even more efficient synthesis of high-purity Ace-K Compl. ¶35

2. Key Claims at a Glance

  • The complaint asserts independent claim 1 Compl. ¶94
  • Essential elements of claim 1 include:
    • A process for producing a finished acesulfame potassium composition.
    • (a) providing a solvent and a cyclizing agent at initial temperatures.
    • (b) contacting them to form a cyclizing agent composition.
    • (c) reacting an acetoacetamide salt with the cyclizing agent composition, wherein prior to this reaction, the cyclizing agent composition has a temperature that is lower than the initial temperatures from step (a).
    • (d) forming a finished composition with less than 35 wppm 5-chloro-acesulfame potassium.
    • A "wherein" clause requiring the contact time from the beginning of step (b) to the beginning of step (c) to be less than 60 minutes.
  • The complaint does not explicitly reserve the right to assert dependent claims for this patent.

3. Multi-Patent Capsules

  • Patent Identification: U.S. Patent No. 10,590,098 ("'098 Patent"), "Acesulfame Potassium Compositions and Processes for Producing Same," issued March 17, 2020.

  • Technology Synopsis: This patent is a continuation of the '004 Patent and targets the same problem of 5-chloro-acesulfame potassium impurity formation (Compl. ¶¶26; Compl. ¶33). It claims a similar process involving cooling the cyclizing agent but requires a significantly shorter contact time of "less than 15 minutes" between preparing the agent and reacting it Compl. ¶111

  • Asserted Claims: At least claim 1 Compl. ¶108

  • Accused Features: The complaint alleges on information and belief that Defendants' manufacturing process for its Ace-K product meets the time, temperature, and impurity limitations of the '098 Patent Compl. ¶¶110-116

  • Patent Identification: U.S. Patent No. 10,233,163 ("'163 Patent"), "Acesulfame Potassium Compositions and Processes for Producing Same," issued March 19, 2019.

  • Technology Synopsis: This patent addresses a different impurity: acetoacetamide Compl. ¶¶41-43 It claims a purification process for an already-formed crude Ace-K composition. The process involves specific steps of (b) concentrating the crude composition at a temperature below 90° C. and (c) separating it (e.g., via crystallization) at a temperature at or below 35° C. to yield a finished product with less than 33 wppm acetoacetamide Compl. ¶126

  • Asserted Claims: At least claim 1 Compl. ¶123

  • Accused Features: The complaint alleges that Defendants' process for purifying crude Ace-K uses the temperature-controlled concentrating and separating steps to achieve the claimed low level of acetoacetamide impurity Compl. ¶¶125-131

  • Patent Identification: U.S. Patent No. 10,590,095 ("'095 Patent"), "Acesulfame Potassium Compositions and Processes for Producing Same," issued March 17, 2020.

  • Technology Synopsis: Similar to the '163 Patent, this patent claims a purification process to reduce acetoacetamide impurity from a crude Ace-K composition Compl. ¶¶41-43 It claims a similar sequence of concentrating and separating steps but with different temperature limits: concentrating below 85° C. and separating at or below 20° C., to achieve a final product with less than 33 wppm acetoacetamide Compl. ¶141

  • Asserted Claims: At least claim 1 Compl. ¶138

  • Accused Features: The complaint alleges Defendants' purification process uses the specific temperature parameters claimed in the '095 Patent to reduce acetoacetamide in its final Ace-K product Compl. ¶¶140-145

III. The Accused Instrumentality

A. Product Identification

  • The Accused Product is acesulfame potassium ("Ace-K") manufactured, supplied, and sold by Defendant Anhui Jinhe Industrial Co., Ltd. and its co-defendant distributors Compl. ¶47

B. Functionality and Market Context

  • The Accused Product is a high-intensity, calorie-free artificial sweetener marketed as a substitute for sugar Compl. ¶51 The complaint cites Jinhe's marketing materials, which describe the Accused Product by its chemical formula, C4H4NO4SK, and promote its high purity and stability Compl. ¶47 Compl. ¶52 The complaint includes a figure from the defendant's website showing the chemical structure of the accused "Acesuifame-k" product Compl. ¶47
  • The complaint alleges that Jinhe is a "major manufacturer" and the "largest producer" of Ace-K in the world, holding a "leading position in the global production capacity and market share" Compl. ¶46 Compl. ¶48 The complaint further alleges that Jinhe's product manuals specify impurity levels, including less than 20 wppm of "organic impurity B," which the complaint identifies as 5-chloro Ace-K, and an overall organic impurity level of less than 20 wppm Compl. ¶53 Compl. ¶55 Compl. ¶86

IV. Analysis of Infringement Allegations

A. U.S. Patent No. 10,023,546 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
a process for producing a finished acesulfame potassium composition, the process comprising the steps of: (a) contacting a cyclizing agent and a solvent...to form a cyclizing agent composition; (b) reacting an acetoacetamide salt with the cyclizing agent...to form a cyclic sulfur trioxide adduct; On information and belief, the complaint alleges that the Accused Product is produced using a process that includes the claimed reaction steps of contacting a cyclizing agent with a solvent and reacting the resulting composition with an acetoacetamide salt Compl. ¶82 Compl. ¶83 ¶83 col. 15:43-16:42
and (c) forming from the cyclic sulfur trioxide adduct the finished acesulfame potassium composition comprising non-chlorinated acesulfame potassium and less than 35 wppm 5-chloro-acesulfame potassium; The complaint alleges that the Accused Product is a finished acesulfame potassium composition that contains less than the claimed maximum limit of 35 wppm of the 5-chloro-acesulfame potassium impurity, citing Defendant's product manual which indicates a limit of less than 20 wppm Compl. ¶85 Compl. ¶86 ¶85; ¶86 col. 9:26-30
wherein contact time from the beginning of step (a) to the beginning of step (b) is less than 60 minutes. The complaint alleges on information and belief that the process used to make the Accused Product meets the limitation that the contact time between forming the cyclizing agent composition and reacting it is less than 60 minutes Compl. ¶83 ¶83 col. 10:60-65

B. U.S. Patent No. 10,208,004 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
a process for producing a finished acesulfame potassium composition, the process comprising: (a) providing a solvent at an initial temperature and a cyclizing agent at an initial temperature...; (b) contacting the solvent and the cyclizing agent to form a cyclizing agent composition; On information and belief, the complaint alleges that the Accused Product is produced using a process that includes providing and contacting a solvent and cyclizing agent to form a cyclizing agent composition Compl. ¶96 Compl. ¶97 ¶97 col. 16:13-17
(c) reacting an acetoacetamide salt with the cyclizing agent composition...wherein prior to being reacted with the acetoacetamide salt, the cyclizing agent composition has a temperature that is lower than the initial temperature of the cyclizing agent and/or the initial temperature of the solvent; The complaint alleges on information and belief that the process used to make the Accused Product includes cooling the cyclizing agent composition to a lower temperature before it is reacted with the acetoacetamide salt Compl. ¶97 ¶97 col. 7:51-57
and (d) forming from the cyclic sulfur trioxide adduct the finished acesulfame potassium composition comprising non-chlorinated acesulfame potassium and less than 35 wppm 5-chloro-acesulfame potassium; The complaint alleges that the Accused Product is a finished acesulfame potassium composition containing less than the claimed 35 wppm limit of 5-chloro-acesulfame potassium, citing Defendant's own product manual specifying a limit of less than 20 wppm Compl. ¶99 Compl. ¶100 ¶99; ¶100 col. 9:5-10
wherein contact time from the beginning of step (b) to the beginning of step (c) is less than 60 minutes. The complaint alleges on information and belief that the process used to make the Accused Product meets the limitation that the contact time between forming the cyclizing agent composition and reacting it is less than 60 minutes Compl. ¶97 ¶97 col. 6:35-41
  • Identified Points of Contention:
    • Evidentiary Questions: The infringement allegations for all five patents, which claim chemical processes, are based on "information and belief" regarding the specific steps of Defendant's manufacturing process in China Compl. ¶82 Compl. ¶96 Compl. ¶110 Compl. ¶125 Compl. ¶140 A central issue will be what evidence Plaintiff can obtain or present to prove the precise time, temperature, and reagent-handling parameters used in Defendant's overseas facilities.
    • Scope Questions: The claims in the '546, '004, and '098 patents require the finished product to have "less than 35 wppm 5-chloro-acesulfame potassium." The complaint alleges Defendant's product meets this, citing a product manual that specifies less than 20 wppm for this impurity Compl. ¶86 Compl. ¶100 Compl. ¶114 While this appears to satisfy the claim limitation, the case may explore whether Defendant's final product purity is achieved through the patented synthesis method, through a different synthesis method followed by extensive purification, or a combination thereof.

V. Key Claim Terms for Construction

  • The Term: "contact time"

  • Context and Importance: This term appears in the '546, '004, and '098 patents and is central to the infringement theory for reducing 5-chloro-ace-K impurity. The claims define it with specific start and end points: "from the beginning of step (a) [contacting a cyclizing agent and a solvent] to the beginning of step (b) [reacting an acetoacetamide salt with the cyclizing agent]" '546 Patent, cl. 1 or similar language. Practitioners may focus on this term because the precise factual moments that constitute the "beginning" of these chemical process steps could be subject to debate and expert testimony, determining whether the accused process falls within the claimed time limits (e.g., <60 minutes or <15 minutes).

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The claim language itself provides an explicit definition based on the start of distinct process steps. A party might argue this language should be given its plain and ordinary meaning as understood by a person of ordinary skill in the art of chemical process engineering.
    • Evidence for a Narrower Interpretation: The specification describes specific embodiments and examples, such as where contact time is measured from the moment reactants are fed into a static mixer until they enter a cyclization reactor '546 Patent, example 1 A party could argue these examples inform or limit the scope of what constitutes the "beginning" of each step, potentially narrowing the definition to specific equipment configurations or actions.

  • The Term: "concentrating"

  • Context and Importance: This term is a key step in claim 1 of the '163 and '095 patents, which are directed to purifying crude Ace-K to remove acetoacetamide. The claims require this step to be conducted below a specific temperature (e.g., "below 90° C.") '163 Patent, cl. 1 The definition of what actions constitute "concentrating" is critical to determining when the temperature limitation applies.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The specification describes "concentrating" as an operation to "form a water stream and an intermediate acesulfame potassium composition," for example, by "evaporating the crude acesulfame potassium composition" '163 Patent, cl. 4 A party could argue "concentrating" broadly covers any step that removes water to increase Ace-K concentration.
    • Evidence for a Narrower Interpretation: The detailed description and figures show specific equipment, such as an "evaporator" (e.g., a falling film evaporator), as part of the concentrating step '163 Patent, FIG. 2 '163 Patent, col. 25:11-14 A party might argue that "concentrating" should be limited to the specific types of evaporation or water-removal techniques and equipment disclosed, rather than any method that increases concentration.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that Defendant Jinhe has induced infringement by actively inducing third parties, such as suppliers and distributors, to sell, offer for sale, use, and/or import the Accused Product, knowing it was made by the patented processes Compl. ¶81 Compl. ¶95 Compl. ¶109 Compl. ¶124 Compl. ¶139 This is further supported by allegations that U.S.-based defendants import and distribute the product, receiving shipments from the parent company in China Compl. ¶¶61-64
  • Willful Infringement: Willfulness is not explicitly pleaded as a separate count, but the complaint alleges that Defendants had "actual knowledge" of the asserted patents "at least as early as the filing of this complaint" Compl. ¶79 Compl. ¶93 Compl. ¶107 Compl. ¶122 Compl. ¶137 This allegation primarily supports a claim for post-suit willfulness and enhanced damages.

VII. Analyst's Conclusion: Key Questions for the Case

  • A primary issue will be one of evidentiary proof: As these are process patents asserted against a product made in China, can the Plaintiff develop sufficient evidence to demonstrate that the Defendant's specific, proprietary manufacturing and purification steps-including precise reaction times, cooling protocols, and temperature-controlled concentration-actually practice the limitations of the asserted claims, moving beyond the complaint's "information and belief" allegations?
  • A second core question will relate to causation of purity: For the synthesis-focused patents ('546, '004, '098), does the accused product's low level of 5-chloro-acesulfame potassium result from the patented time- and temperature-controlled synthesis, or from unrelated post-synthesis purification steps? Similarly, for the purification-focused patents ('163, '095), is the low level of acetoacetamide in the final product a result of the specific temperature-controlled concentration and separation steps, or other purification methods?
  • A third question may focus on claim construction: How will the court define the temporal boundaries of the "contact time" limitation? The interpretation of when a process step "begins" could be dispositive for infringement, especially for the '098 patent's narrow "less than 15 minutes" window.
Loading Complaint